dc.contributor.author | Kachowski, Larisa | eng |
dc.contributor.author | Over, Darrell R. | eng |
dc.contributor.author | Qiu, Kefeng | eng |
dc.date.issued | 2012 | eng |
dc.description.abstract | Fluoxetine (Prozac) and orlistat (Xenical) produce modest short-term weight loss, but their long-term benefits are unclear and their safety is uncertain. (Strength of Recommendation [SOR]: B, based on a meta-analysis of randomized controlled trials.) Topiramate (Topamax; immediate- and controlled-release formulations) can produce weight loss, but potential psychiatric and neurologic adverse effects limit its usefulness (SOR: B, based on randomized controlled trials.) Sibutramine (Meridia) produces weight loss but has been withdrawn from the U.S. market because of potential cardiovascular adverse effects. | eng |
dc.identifier.uri | http://hdl.handle.net/10355/13372 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2012 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. | eng |
dc.relation.ispartofseries | American family physician, 85, no. 06 (March 2012): 633-635. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject.lcsh | Insulin resistance | eng |
dc.subject.lcsh | Weight loss | eng |
dc.subject.lcsh | Drugs -- Therapeutic use | eng |
dc.title | Medications for weight loss in patients with Type 2 diabetes mellitus | eng |
dc.type | Article | eng |